Transforming growth factor beta in cardiovascular development and function

Cytokine and Growth Factor Reviews

Volumn 14, Issue 5, 2003, Pages 391-407

  Azhar, Mohamad ^a   Schultz, Jo El J ^a   Grupp, Ingrid ^a   Dorn II, Gerald W ^a   Meneton, Pierre ^b   Molin, Daniel G M ^c   Gittenberger de Groot, Adriana C ^c   Doetschman, Thomas ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b INSERM   (France)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Development; Heart; Physiology; TGF ; Vasculature

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CYTOKINE; RENIN; TRANSFORMING GROWTH FACTOR BETA;

BLOOD PRESSURE; CALCIUM SIGNALING; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CELL TRANSFORMATION; CHROMOSOME 22Q; CONGENITAL HEART DISEASE; CORONARY BLOOD VESSEL; EMBRYO DEVELOPMENT; ENDOCARDIAL CUSHION DEFECT; EPICARDIUM; EPITHELIUM; EXPLANT; GENETIC ENGINEERING; HEART DEVELOPMENT; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; KIDNEY DISEASE; MESENCHYME; NEURAL CREST CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

EID: 0042876796     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(03)00044-3     Document Type: Review

References (150)

1. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000;14:627-44.
2. Sporn MB, Roberts AB. Transforming growth factor-beta: recent progress and new challenges. J Cell Biol 1992;119:1017-21 [review].
3. Heine U, Munoz EF, Flanders KC, Ellingsworth LR, Lam HY, Thompson NL, et al. Role of transforming growth factor-beta in the development of the mouse embryo. J Cell Biol 1987;105:2861-76.
4. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI. Immunohistochemical localization of TGF beta 1-3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol 1991;115:1091-105.
5. Sanford LP, Ormsby I, Gittenberger-de GA, Sariola H, Friedman R, Boivin GP, et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997;124:2659-70.
6. Dunker N, Krieglstein K. Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis. Eur J Biochem 2000;267:6982-8.
7. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs): structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Fact Rev 1999;10:99-117.
8. Wrana JL. TGF-beta receptors and signalling mechanisms. Miner Electrolyte Metab 1998;24:120-30.
9. Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA. Expression cloning and characterization of the TGF-beta type III receptor. Cell 1991;67:797-805.
10. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992;267:19027-30.
11. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 1991;67:785-95.
12. Lopez-Casillas F, Payne HM, Andres JL, Massague J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 1994;124:557-68.
13. Rotzer D, Roth M, Lutz M, Lindemann D, Sebald W, Knaus P. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J 2001;20:480-90.
14. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, et al. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 1996;133:1109-21.
15. Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Technol 2001;52:437-49.
16. Moustakas A, Heldin CH. From mono- to oligo-Smads: the heart of the matter in TGF-β signal transduction. Genes Dev 2002;16:1867-71.
17. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Fact Rev 2000;11:23-35.
18. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998;95:737-40.
19. Nesti LJ, Caterson EJ, Wang M, Chang R, Chapovsky F, Hoek JB, et al. TGF-beta1-stimulated osteoblasts require intracellular calcium signaling for enhanced alpha5 integrin expression. Ann NY Acad Sci 2002;961:178-82.
20. Hoying JB, Yin M, Diebold R, Ormsby I, Becker A, Doetschman T. Transforming growth factor beta1 enhances platelet aggregation through a non-transcriptional effect on the fibrinogen receptor. J Biol Chem 1999;274:31008-13.
21. Whitman M, Mercola M. TGF-beta superfamily signaling and left-right asymmetry. Science STKE; 2001. http://www.stke.org/cgi/content/full/OC_sigtrans2001;/64/re1.
22. Hamada H, Meno C, Watanabe D, Saijoh Y. Establishment of vertebrate left-right asymmetry. Nat Rev Genet 2002;3:103-13.
23. Schneider MD, Gaussin V, Lyons KM. Tempting fate: BMP signals for cardiac morphogenesis. Cytokine Growth Fact Rev 2003;14:1-4.
24. MacLellan WR, Brand T, Schneider MD. Transforming growth factor-beta in cardiac ontogeny and adaptation. Circ Res 1993;73:783-91.
25. McDermid HE, Morrow BE. Genomic disorders on 22q11. Am J Hum Genet 2002;70:1077-88.
26. Dickson MC, Slager HG, Duffie E, Mummery CL, Akhurst RJ. RNA and protein localisations of TGF beta 2 in the early mouse embryo suggest an involvement in cardiac development. Development 1993;117:625-39.
27. Camenisch TD, Molin DG, Person A, Runyan RB, Gittenberger-de Groot AC, McDonald JA, et al. Temporal and distinct TGFbeta ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol 2002;248:170-81.
28. Molin DG, DeRuiter MC, Wisse LJ, Azhar M, Doetschman T, Poelmann RE, et al. Altered apoptosis pattern during pharyngeal arch artery remodelling is associated with aortic arch malformations in Tgfbeta2 knock-out mice. Cardiovasc Res 2002;56:312-22.
29. Lough J, Sugi Y. Endoderm and heart development. Dev Dyn 2000;217:327-42.
30. Sugi Y, Markwald RR. Early endocardial formation originates from precardiac mesoderm as revealed by QH-I antibody staining. Ital J Anat Embryol 1995;100(Suppl 1):263-72.
31. Brown CB, Drake CJ, Barnett JV. Antibodies directed against the chicken type II TGFbeta receptor identify endothelial cells in the developing chicken and quail. Dev Dyn 1999;215:79-85.
32. Bouman HG, Broekhuizen ML, Baasten AM, Gittenberger-de Groot AC, Wenink AC. Spectrum of looping disturbances in stage 34 chicken hearts after retinoic acid treatment. Anat Rec 1995;243:101-8.
33. Bartram U, Molin DG, Wisse LJ, Mohamad A, Sanford LP, Doetschman T, et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in Tgfb2 knockout mice. Circulation 2001;103:2745-52.
34. Mjaatvedt CH, Yamamura H, Wessels A, Ramsdell A, Turner D, Markwald RR. Mechanisms of segmentation, septation, and remodeling of the tubular heart: endocardial cushion fate and cardiac looping. In: Harvey RP, Rosenthal N, editors. Heart development. New York: Academic Press; 1999. p. 159-77.
35. Runyan RB, Markwald RR. Invasion of mesenchyme into three-dimensional collagen gels: a regional and temporal analysis of interaction in embryonic heart tissue. Dev Biol 1983;95:108-14.
36. Potts JD, Runyan RB. Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor beta. Dev Biol 1989;134:392-401.
37. Eisenberg LM, Markwald RR. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 1995;77:1-6.
38. Huang JX, Potts JD, Vincent EB, Weeks DL, Runyan RB. Mechanisms of cell transformation in the embryonic heart. Ann NY Acad Sci 1995;752:317-30.
39. Boyer AS, Ayerinskas II, Vincent EB, McKinney LA, Weeks DL, Runyan RB. TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol 1999;208:530-45.
40. Boyer AS, Erickson CP, Runyan RB. Epithelial-mesenchymal transformation in the embryonic heart is mediated through distinct pertussis toxin-sensitive and TGFbeta signal transduction mechanisms. Dev Dyn 1999;214:81-91.
41. Brown CB, Boyer AS, Runyan RB, Barnett JV. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 1999;283:2080-2.
42. Boyer AS, Runyan RB. TGFbeta Type III and TGFbeta Type II receptors have distinct activities during epithelial-mesenchymal cell transformation in the embryonic heart. TA, Dev Dyn 2001;221:454-9.
43. Akhurst RJ, Lehnert SA, Faissner A, Duffie E. TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 1990;108:645-56.
44. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
45. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-4.
46. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci USA 2001;98:6686-91.
47. Nakajima Y, Yamagishi T, Hokari S, Nakamura H. Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec 2000;258:119-27.
48. Kim RY, Robertson EJ, Solloway MJ. Bmp6 and Bmp7 are required for cushion formation and septation in the developing mouse heart. Dev Biol 2001;235:449-66.
49. Gaussin V, Van de PT, Mishina Y, Hanks MC, Zwijsen A, Huylebroeck D, et al. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc Natl Acad Sci USA 2002;99:2878-83.
50. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 2000;24:171-4.
51. Viragh S, Challice CE. The origin of the epicardium and the embryonic myocardial circulation in the mouse. Anat Rec 1981;201:157-68.
52. Dettman RW, Denetclaw Jr W, Ordahl CP, Bristow J. Common epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial fibroblasts in the avian heart. Dev Biol 1998;193:169-81.
53. Gittenberger-de Groot AC, Vrancken Peeters MP, Mentink MM, Gourdie RG, Poelmann RE. Epicardium-derived cells contribute a novel population to the myocardial wall and the atrioventricular cushions. Circ Res 1998;82:1043-52.
54. Morabito CJ, Dettman RW, Kattan J, Collier JM, Bristow J. Positive and negative regulation of epicardial mesenchymal transformation during avian heart development. Dev Biol 2001;234:204-15.
55. Bartelings MM, Gittenberger-de Groot AC. The outflow tract of the heart: embryologic and morphologic correlations. Int J Cardiol 1989;22:289-300.
56. Lamers WH, Viragh S, Wessels A, Moorman AF, Anderson RH. Formation of the tricuspid valve in the human heart. Circulation 1995;91:111-21.
57. Rosenquist TH, Fray-Gavalas C, Waldo K, Beall AC. Development of the musculoelastic septation complex in the avian truncus arteriosus. Am J Anat 1990;189:339-56.
58. van den Hoff MJ, Moorman AF, Ruijter JM, Lamers WH, Bennington RW, Markwald RR, et al. Myocardialization of the cardiac outflow tract. Dev Biol 1999;212:477-90.
59. Poelmann RE, Mikawa T, Gittenberger-de Groot AC. Neural crest cells in outflow tract septation of the embryonic chicken heart: differentiation and apoptosis. Dev Dyn 1998;212:373-84.
60. Poelmann RE, Molin D, Wisse LJ, Gittenberger-de GA. Apoptosis in cardiac development. Cell Tissue Res 2000;301:43-52.
61. Siman CM, Gittenberger-de Groot AC, Wisse B, Eriksson UJ. Malformations in offspring of diabetic rats: morphometric analysis of neural crest-derived organs and effects of maternal Vitamin E treatment. Teratology 2000;61:355-67.
62. Waller III BR, McQuinn T, Phelps AL, Markwald RR, Lo CW, Thompson RP, et al. Conotruncal anomalies in the trisomy 16 mouse: an immunohistochemical analysis with emphasis on the involvement of the neural crest. Anat Rec 2000;260:279-93.
63. Hogers B, DeRuiter MC, Gittenberger-de Groot AC, Poelmann RE. Extraembryonic venous obstructions lead to cardiovascular malformations and can be embryolethal. Cardiovasc Res 1999;41:87-99.
64. Armstrong PB, Armstrong MT. Intercellular invasion and the organizational stability of tissues: a role for fibronectin. Biochim Biophys Acta 2000;1470:9-20.
65. Zhang HY, Chu ML, Pan TC, Sasaki T, Timpl R, Ekblom P. Extracellular matrix protein fibulin-2 is expressed in the embryonic endocardial cushion tissue and is a prominent component of valves in adult heart. Dev Biol 1995;167:18-26.
66. Le Lievre CS, Le Douarin NM. Mesenchymal derivatives of the neural crest: analysis of chimeric quail and chick embryos. J Embryol Exp Morphol 1975;34:125-54.
67. Kirby ML, Waldo KL. Role of neural crest in congenital heart disease. Circulation 1990;82:332-40.
68. Maschhoff KL, Baldwin HS. Molecular determinants of neural crest migration. Am J Med Genet 2000;97:280-8.
69. Pexieder T. Cell death in the morphogenesis and teratogenesis of the heart. Adv Anat Embr Cell Biol 1975;51:1-100.
70. Garcia-Castro M, Bronner-Fraser M. Induction and differentiation of the neural crest. Curr Opin Cell Biol 1999;11:695-8.
71. Brauer PR, Yee JA. Cranial neural crest cells synthesize and secrete a latent form of transforming growth factor beta that can be activated by neural crest cell proteolysis. Dev Biol 1993;155:281-5.
72. Jiang X, Rowitch DH, Soriano P, McMahon AP, Sucov HM. Fate of the mammalian cardiac neural crest. Development 2000;127:1607-16.
73. de Ruiter MC, Gittenberger-de Groot AC, Rammos S, Poelmann RE. The special status of the pulmonary arch artery in the branchial arch system of the rat. Anat Embryol (Berl) 1989;179:319-25.
74. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995;11:409-14.
75. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995;11:415-21.
76. Moene RJ, Gittenberger-de Groot AC, Oppenheimer-Dekker A, Bartelings MM. Anatomic characteristics of ventricular septal defect associated with coarctation of the aorta. Am J Cardiol 1987;59:952-5.
77. Meeson A, Palmer M, Calfon M, Lang R. A relationship between apoptosis and flow during programmed capillary regression is revealed by vital analysis. Development 1996;122:3929-38.
78. Topouzis S, Majesky MW. Smooth muscle lineage diversity in the chick embryo: two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta. Dev Biol 1996;178:430-45.
79. Owens GK. Molecular control of vascular smooth muscle cell differentiation. Acta Physiol Scand 1998;164:623-35.
80. Waldo KL, Kumiski D, Kirby ML. Cardiac neural crest is essential for the persistence rather than the formation of an arch artery. Dev Dyn 1996;205:281-92.
81. Cameron AM, Nucifora FCJ, Fung ET, Livingston DJ, Aldape RA, Ross CA, et al. FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. J Biol Chem 1997;272:27582-8.
82. Shou W, Aghdasi B, Armstrong DL, Guo Q, Bao S, Charng MJ, et al. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 1998;391:489-92.
83. de la Pompa JL, Timmerman LA, Takimoto H, Yoshida H, Elia AJ, Samper E, et al. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 1998;392:182-6.
84. Ranger AM, Grusby MJ, Hodge MR, Gravallese EM, de la Brousse FC, Hoey T, et al. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 1998;392:186-90.
85. 2+-calcineurin-mediated activation in thymocytes. J Immunol 2003;170:3645-52.
86. Goldmuntz E, Emanuel BS. Genetic disorders of cardiac morphogenesis: the DiGeorge and velocardiofacial syndromes. Circ Res 1997;80:437-43.
87. Farrell MJ, Stadt H, Wallis KT, Scambler P, Hixon RL, Wolfe R, et al. HIRA: a DiGeorge syndrome candidate gene, is required for cardiac outflow tract septation. Circ Res 1999;84:127-35.
88. Lindsay EA, Vitelli F, Su H, Morishima M, Huynh T, Pramparo T, et al. Tbx1 haploinsufficieny in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 2001;410:97-101.
89. Kardami E. Stimulation and inhibition of cardiac myocyte proliferation in vitro. Mol Cell Biochem 1990;92:129-35.
90. Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 1992;262:H1861-6.
91. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts: regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991;69:483-90.
92. Parker TG, Packer SE, Schneider MD. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990;85:507-14.
93. Ruwhof C, van Wamel AE, Egas JM, van der LA. Cyclic stretch induces the release of growth promoting factors from cultured neonatal cardiomyocytes and cardiac fibroblasts. Mol Cell Biochem 2000;208:89-98.
94. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-61.
95. Zhu Z, Tepel M, Neusser M, Zidek W. Transforming growth factor beta 1 modulates angiotensin II-induced calcium influx in vascular smooth muscle. Eur J Clin Invest 1995;25:317-21.
96. Xu C, Lee S, Singh TM, Sho E, Li X, Sho M, et al. Molecular mechanisms of aortic wall remodeling in response to hypertension. J Vasc Surg 2001;33:570-8.
97. Song RH, Kocharyan HK, Fortunato JE, Glagov S, Bassiouny HS. Increased flow and shear stress enhance in vivo transforming growth factor-beta1 after experimental arterial injury. Arterioscler Thromb Vasc Biol 2000;20:923-30.
98. Nicholls MG, Robertson JI. The renin-angiotensin system in the year 2000. J Hum Hypertens 2000;14:649-66.
99. Ray PE, McCune BK, Gomez RA, Horikoshi S, Kopp JB, Klotman PE. Renal vascular induction of TGF-beta 2 and renin by potassium depletion. Kidney Int 1993;44:1006-13.
100. Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure: the Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996;28:881-7.
101. Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000;97:3479-84.
102. Ohta K, Kim S, Hamaguchi A, Yukimura T, Miura K, Takaori K, et al. Role of angiotensin II in extracellular matrix and transforming growth factor-beta 1 expression in hypertensive rats. Eur J Pharmacol 1994;269:115-9.
103. Schultz JJ, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002;109:787-96.
104. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002;283:H1253-62.
105. Grupp IL, Subramaniam A, Hewett TE, Robbins J, Grupp G, Comparison of normal, hypodynamic, and hyperdynamic mouse hearts using isolated work-performing heart preparations. Am J Physiol 1993;265:H1401-1410.
106. Long CS, Hartogensis WE, Simpson PC. Beta-adrenergic stimulation of cardiac non-myocytes augments the growth-promoting activity of non-myocyte conditioned medium. J Mol Cell Cardiol 1993;25:915-25.
107. Taimor G, Uter KD, Frischkopf K, Flesch M, Rosenkranz S, Piper HM. Autocrine regulation of TGF beta expression in adult cardiomyocytes. J Mol Cell Cardiol 1999;31:2127-36.
108. Nogami M, Romberger DJ, Rennard SI, Toews ML. TGF-beta 1 modulates beta-adrenergic receptor number and function in cultured human tracheal smooth muscle cells. Am J Physiol 1994;266: L187-91.
109. Miki N, Hamamori Y, Hirata K, Suematsu M, Kawashima S, Akita H, et al. Transforming growth factor-beta 1 potentiated alpha 1-adrenergic and stretch-induced c-fos MRNA expression in rat myocardial cells. Circ Res 1994;75:8-14.
110. Li RK, Li G, Mickle DA, Weisel RD, Merante F, Luss H, et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997;96:874-81.
111. Kupfahl C, Pink D, Friedrich K, Zurbrugg HR, Neuss M, Warnecke C, et al. Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res 2000;46:463-75.
112. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 1998;40:352-63.
113. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 1995;27:2347-57.
114. Sadoshima J, Izumo S. Molecular characterization of angiotensin II: induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts, critical role of the AT1 receptor subtype. Circ Res 1993;73:413-23.
115. Patel R, Lim DS, Reddy D, Nagueh SF, Lutucuta S, Sole MJ, et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000;32:2369-77.
116. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, et al. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci USA 1995;92:12215-9.
117. Tsuchimochi H, Sugi M, Kuro-o M, Ueda S, Takaku F, Furuta S, et al. Isozymic changes in myosin of human atrial myocardium induced by overload. Immunohistochemical study using monoclonal antibodies. J Clin Invest 1984;74:662-5.
118. Lompre AM, Mercadier JJ, Schwartz K. Changes in gene expression during cardiac growth. Int Rev Cytol 1991;124:137-86.
119. Izumo S, Lompre AM, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B, et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy: interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 1987;79:970-7.
120. Susic D, Nunez E, Frohlich ED, Prakash O. Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Hypertension 1996;28:265-8.
121. Schultz JJ, Witt SA, Nieman ML, Reiser PJ, Engle SJ, Zhou M, et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest 1999;104:709-19.
122. Schmidt A, Gopfert C, Vlodavsky I, Volker W, Buddecke E. Induction of a hypertrophic growth status of coronary smooth muscle cells is associated with an overexpression of TGF-beta. Eur J Cell Biol 2002;81:138-44.
123. Bouillier H, Samain E, Miserey S, Perret C, Renaud JF, Safar M, et al. Transforming growth factor-beta1 modulates angiotensin II-induced calcium release in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2000;18:733-42.
124. Ali S, Davis MG, Becker MW, Dorn 2 GW. Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 1993;268:17397-403.
125. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993;91:2268-74.
126. Davis MG, Zhou M, Ali S, Coffin JD, Doetschman T, Dorn GW. Intracrine and autocrine effects of basic fibroblast growth factor in vascular smooth muscle cells. J Mol Cell Cardiol 1997;29:1061-72.
127. Kanzaki T, Tamura K, Takahashi K, Saito Y, Akikusa B, Oohashi H, et al. In vivo effect of TGF-beta 1: enhanced intimal thickening by administration of TGF-beta 1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol 1995;15:1951-7.
128. Merrilees M, Beaumont B, Scott L, Hermanutz V, Fennessy P. Effect of TGF-beta(1) antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries. J Vasc Res 2000;37:50-60.
129. Chen YL, Wu HW, Jiang MJ. Transforming growth factor-beta1 gene and protein expression associated with atherogenesis of cholesterol-fed rabbits. Histol Histopathol 2000;15:421-8.
130. Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel J, Heldin CH, et al. Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J Cell Biol 1993;120:995-1002.
131. Paiement P, Bertrand O, Scortichini D, Meerkin D, Cloutier MJ, Methot D, et al. Local delivery of TGF-b antibodies to prevent neointima formation after balloon injury in a pig coronary artery model. J Invasive Cardiol 1998;10:470-6.
132. Wahl SM, Orenstein JM, Chen W. TGF-beta influences the life and death decisions of T lymphocytes. Cytokine Growth Fact Rev 2000;11:71-9.
133. Koglin J, Glysing-Jensen T, Raisanen-Sokolowski A, Russell ME. Immune sources of transforming growth factor-beta1 reduce transplant arteriosclerosis: insight derived from a knockout mouse model. Circ Res 1998;83:652-60.
134. Kurtz A, Wagner C. Cellular control of renin secretion. J Exp Biol 1999;202:219-25.
135. Allikmets K, Parik T, Viigimaa M. The renin-angiotensin system in essential hypertension: associations with cardiovascular risk. Blood Press 1999;8:70-8.
136. Farmer JA. Renin-angiotensin system and ASCVD. Curr Opin Cardiol 2000;15:141-50.
137. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab 1998;24:381-8.
138. Horikoshi S, McCune BK, Ray PE, Kopp JB, Sporn MB, Klotman PE. Water deprivation stimulates transforming growth factor-beta 2 accumulation in the juxtaglomerular apparatus of mouse kidney. J Clin Invest 1991;88:2117-22.
139. Antonipillai I, Horton R. Paracrine regulation of the renin-aldosterone system. J Steroid Biochem Mol Biol 1993;45:27-31.
140. Pietri L, Bloch-Faure M, Belair MF, Sanford LP, Doetschman T, Menard J, et al. Altered renin synthesis and secretion in the kidneys of heterozygous mice with a null mutation in the TGF-beta(2) gene. Exp Nephrol 2002;10:374-82.
141. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Nat Acad Sci USA 1986;83:4167-71.
142. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
143. Boivin GP, O'Toole BA, Orsmby IE, Diebold RJ, Eis MJ, Doetschman T, et al. Onset and progression of pathological lesions in transforming growth factor-beta 1-deficient mice. Am J Pathol 1995;146:276-88.
144. Nakajima H, Nakajima HO, Salcher O, Dittie AS, Dembowsky K, Jing S, et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res 2000;86:571-9.
145. Omura T, Kim S, Takeuchi K, Iwao H, Takeda T. Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. Cardiovasc Res 1994;28:1835-42.
146. Brooks WW, Conrad CH. Myocardial fibrosis in transforming growth factor beta(1) heterozygous mice. J Mol Cell Cardiol 2000;32:187-95.
147. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM. Decreased Smad7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2002;282: H1685-96.
148. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998;31:181-8.
149. Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int 2000;58:2367-76.
150. Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001;170:647-51.